Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 357

1.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.

Cesne AL, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H.

BMC Cancer. 2019 Aug 13;19(1):794. doi: 10.1186/s12885-019-5988-3.

2.

Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre.

Drabbe C, Benson C, Younger E, Zaidi S, Jones RL, Judson I, Chisholm J, Mandeville H, Fisher C, Thway K, Al Muderis O, Messiou C, Strauss D, Husson O, Miah A, Van der Graaf WTA.

Clin Oncol (R Coll Radiol). 2019 Jul 23. pii: S0936-6555(19)30287-0. doi: 10.1016/j.clon.2019.07.007. [Epub ahead of print]

PMID:
31350181
3.

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L, Hennig I, Jarman K, Joubert W, Kernaghan S, López Pousa A, McNeil C, Seddon B, Snowdon C, Tattersall M, Toms C, Martinez Trufero J, Bliss JM.

Lancet Oncol. 2019 Jul;20(7):1023-1034. doi: 10.1016/S1470-2045(19)30215-3. Epub 2019 May 31.

4.

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.

Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 2019 Mar;109:51-60. doi: 10.1016/j.ejca.2018.12.009. Epub 2019 Jan 25.

PMID:
30690293
5.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C.

Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.

6.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

7.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

8.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

9.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators.

J Clin Oncol. 2018 Sep 6:JCO2018782516. doi: 10.1200/JCO.2018.78.2516. [Epub ahead of print]

10.

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P.

Cancer Chemother Pharmacol. 2018 Nov;82(5):911-912. doi: 10.1007/s00280-018-3674-9.

PMID:
30173339
11.

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.

Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL.

Med Oncol. 2018 Aug 20;35(10):131. doi: 10.1007/s12032-018-1193-5.

12.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78. doi: 10.1093/annonc/mdy095. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267.

PMID:
29846513
13.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67. doi: 10.1093/annonc/mdy096. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269.

PMID:
29846498
14.

Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study.

Zhang AY, Judson I, Benson C, Wunder JS, Ray-Coquard I, Grimer RJ, Quek R, Wong E, Miah AB, Ferguson PC, Dufresne A, Teh JYH, Stockler M, Tattersall MHN.

Br J Cancer. 2018 Jun;118(12):1682. doi: 10.1038/s41416-018-0079-9.

15.

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.

Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, Thomas K, Moskovic E, Szucs Z, Benson C, Messiou C.

Clin Sarcoma Res. 2018 May 14;8:13. doi: 10.1186/s13569-018-0100-3. eCollection 2018.

16.

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.

Verschoor AJ, Litière S, Marréaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, Gronchi A, Gelderblom H.

Eur J Cancer. 2018 May;94:187-198. doi: 10.1016/j.ejca.2018.02.015. Epub 2018 Mar 22.

PMID:
29574364
17.

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.

Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):448-454. doi: 10.1016/j.clon.2018.02.065. Epub 2018 Mar 15.

18.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Aug;57(8):1117-1126. doi: 10.1080/0284186X.2018.1449248. Epub 2018 Mar 9.

PMID:
29521151
19.

Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series.

Cohen-Hallaleh RB, Smith HG, Smith RC, Stamp GF, Al-Muderis O, Thway K, Miah A, Khabra K, Judson I, Jones R, Benson C, Hayes AJ.

Clin Sarcoma Res. 2017 Aug 7;7:15. doi: 10.1186/s13569-017-0081-7. eCollection 2017.

20.

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study.

Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra M, Mungul A, Manson SC, Sanfilippo R.

Acta Oncol. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 2017 Jul 19.

PMID:
28723233
21.

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study.

Zhang AY, Judson I, Benson C, Wunder JS, Ray-Coquard I, Grimer RJ, Quek R, Wong E, Miah AB, Ferguson PC, Dufresne A, Teh JYH, Stockler M, Tattersall MHN.

Br J Cancer. 2017 Jul 25;117(3):326-331. doi: 10.1038/bjc.2017.198. Epub 2017 Jun 27. Erratum in: Br J Cancer. 2018 Jun;118(12):1682.

22.

UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).

Judson I, Bulusu R, Seddon B, Dangoor A, Wong N, Mudan S.

Clin Sarcoma Res. 2017 Apr 21;7:6. doi: 10.1186/s13569-017-0072-8. eCollection 2017.

23.

Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.

Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G, Daugaard S, Sciot R, Collin F, Messiou C, Grünwald V, Gronchi A, van der Graaf W, Wardelmann E, Judson I.

Acta Oncol. 2017 Jul;56(7):1013-1020. doi: 10.1080/0284186X.2017.1315173. Epub 2017 Apr 21.

24.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
25.

Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts.

van der Graaf WTA, Orbach D, Judson IR, Ferrari A.

Lancet Oncol. 2017 Mar;18(3):e166-e175. doi: 10.1016/S1470-2045(17)30099-2. Epub 2017 Mar 2. Review.

PMID:
28271871
26.

The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities.

Noujaim J, Jones RL, Swansbury J, Gonzalez D, Benson C, Judson I, Fisher C, Thway K.

Br J Cancer. 2017 Feb 28;116(5):669-678. doi: 10.1038/bjc.2017.4. Epub 2017 Jan 31.

27.

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26457. Epub 2017 Jan 23. Review.

PMID:
28111876
28.

Pazopanib, a promising option for the treatment of aggressive fibromatosis.

Szucs Z, Messiou C, Wong HH, Hatcher H, Miah A, Zaidi S, van der Graaf WT, Judson I, Jones RL, Benson C.

Anticancer Drugs. 2017 Apr;28(4):421-426. doi: 10.1097/CAD.0000000000000474.

29.

Symptom Burden in Advanced Soft-Tissue Sarcoma.

Gough N, Koffman J, Ross JR, Riley J, Judson I.

J Pain Symptom Manage. 2017 Mar;53(3):588-597. doi: 10.1016/j.jpainsymman.2016.10.357. Epub 2016 Dec 29.

PMID:
28042077
30.

UK guidelines for the management of soft tissue sarcomas.

Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I.

Clin Sarcoma Res. 2016 Nov 15;6:20. eCollection 2016. Review.

31.

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.

J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.

PMID:
27621408
32.

Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance.

Lee YF, Roe T, Mangham DC, Fisher C, Grimer RJ, Judson I.

Br J Cancer. 2016 Oct 11;115(8):1000-1007. doi: 10.1038/bjc.2016.280. Epub 2016 Sep 8.

33.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.

PMID:
27498913
34.

Sarcoma: Olaratumab - really a breakthrough for soft-tissue sarcomas?

Judson I, van der Graaf WT.

Nat Rev Clin Oncol. 2016 Sep;13(9):534-6. doi: 10.1038/nrclinonc.2016.123. Epub 2016 Aug 2. No abstract available.

PMID:
27480665
35.

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas.

Vitfell-Rasmussen J, Judson I, Safwat A, Jones RL, Rossen PB, Lind-Hansen M, Knoblauch P, Krarup-Hansen A.

Sarcoma. 2016;2016:2090271. doi: 10.1155/2016/2090271. Epub 2016 Jun 14.

36.

Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.

Grünwald V, Litière S, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, Gronchi A, Judson I; EORTC STBSG.

Eur J Cancer. 2016 Sep;64:44-51. doi: 10.1016/j.ejca.2016.05.023. Epub 2016 Jun 17.

PMID:
27323349
37.

Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.

Ray-Coquard I, Rizzo E, Blay JY, Casali P, Judson I, Hansen AK, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Litière S, Rutkowski P, Hohenberger P, Gronchi A, van der Graaf WT.

Gynecol Oncol. 2016 Jul;142(1):95-101. doi: 10.1016/j.ygyno.2016.05.016. Epub 2016 May 24.

PMID:
27208537
38.

ALK-positive inflammatory myofibroblastic tumor harboring ALK gene rearrangement, occurring after allogeneic stem cell transplant in an adult male.

Vroobel K, Judson I, Dainton M, McCormick A, Fisher C, Thway K.

Pathol Res Pract. 2016 Aug;212(8):743-6. doi: 10.1016/j.prp.2016.04.007. Epub 2016 Apr 26.

PMID:
27155927
39.

UK guidelines for the management of bone sarcomas.

Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, Peake D, Seddon B, Whelan J; British Sarcoma Group.

Clin Sarcoma Res. 2016 May 4;6:7. doi: 10.1186/s13569-016-0047-1. eCollection 2016. Review.

40.

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla S, Gil T, Piperno-Neumann S, Marréaud S, Dewji MR, van der Graaf WTA.

Gynecol Oncol. 2016 Jul;142(1):89-94. doi: 10.1016/j.ygyno.2016.03.024. Epub 2016 Apr 29.

PMID:
27012429
41.

Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.

Vlenterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom H, Le Cesne A, Wardelmann E, Messiou C, Gronchi A, van der Graaf WT.

Eur J Cancer. 2016 May;58:62-72. doi: 10.1016/j.ejca.2016.02.002. Epub 2016 Mar 8.

PMID:
26968015
42.

Systemic Treatment of Liposarcomas: Light at the End of the Tunnel?

Constantinidou A, Judson I.

J Oncol Pract. 2016 Mar;12(3):228-9. doi: 10.1200/JOP.2015.010140. No abstract available.

PMID:
26962164
43.

p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?

Noujaim J, Gonzalez D, Thway K, Jones RL, Judson I.

Cancer Biol Ther. 2016 May 3;17(5):543-5. doi: 10.1080/15384047.2016.1156263. Epub 2016 Mar 4.

44.

Phosphoproteomics in translational research: a sarcoma perspective.

Noujaim J, Payne LS, Judson I, Jones RL, Huang PH.

Ann Oncol. 2016 May;27(5):787-94. doi: 10.1093/annonc/mdw030. Epub 2016 Jan 22. Review.

PMID:
26802162
45.

Phase I trial outcomes in older patients with advanced solid tumours.

Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB.

Br J Cancer. 2016 Feb 2;114(3):262-8. doi: 10.1038/bjc.2015.477. Epub 2016 Jan 12.

46.

'When something is this rare … how do you know bad really is bad…?'-views on prognostic discussions from patients with advanced soft tissue sarcoma.

Gough N, Ross JR, Riley J, Judson I, Koffman J.

BMJ Support Palliat Care. 2019 Mar;9(1):100-107. doi: 10.1136/bmjspcare-2015-000898. Epub 2015 Dec 28.

PMID:
26715566
47.

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.

J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16.

PMID:
26573069
48.

Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.

Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL.

Am J Clin Oncol. 2018 Feb;41(2):147-151. doi: 10.1097/COC.0000000000000243.

PMID:
26523439
49.

Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.

Noujaim J, Thway K, Jones RL, Miah A, Khabra K, Langer R, Kasper B, Judson I, Benson C, Kollàr A.

Anticancer Res. 2015 Nov;35(11):6213-7.

PMID:
26504053
50.

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT.

Eur J Cancer. 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25.

PMID:
26321011

Supplemental Content

Loading ...
Support Center